CHRS Q2 2022 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M-31.4% YoY

Gross Profit

$49M81.3% margin

Operating Income

-$44M-73.2% margin

Net Income

-$50M-83.4% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

+0.1%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$51M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$546M

Total Liabilities

$569M

Stockholders' Equity

-$23M

Cash & Equivalents

$275M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$88M	-31.4%
Gross Profit	$49M	$71M	-31.1%
Operating Income	-$44M	-$24M	-82.1%
Net Income	-$50M	-$30M	-67.7%